Table 1.

Overview of cohorts in the Glitipni trial.

Cohort	Additional eligibility criteria	Recruitment Status	No. of patients	Study Treatment			Recruitment period
				Per-operative		Post-operative*	2017	2018	2019	2020	2021	2022	2023
1	Resectable	Completed	3	MSR	iCer 10 mg IPI	IV 10 mg NIVO Q2w x6
2		Completed	24	MSR	iCer 5 mg IPI + 10 mg NIVO
3	Unresectable	Completed	16	STx	iTum 5 mg IPI + 10 mg NIVO	IV 10 mg NIVO + iCav 1/5/10 mg NIVO Q2w x12
4	Resectable	Completed	16	MSR	iCer 5 mg IPI + 10 mg NIVO
5	Resectable	Paused	11	MSR	iCer 5 mg IPI + 10 mg NIVO iCer myDC (1- 10- 20.106)	IV 10 mg NIVO + iCav 10 mg NIVO Q2w x12
6	Unresectable	Discontinued	2	STx	iTum 5 mg IPI + 10 mg NIVO iTum myDC
7	Resectable	Ongoing	27+	MSR	iCer 5 mg IPI + 10 mg NIVO	IV 10 mg NIVO + iCav 10 mg NIVO + iCav 1/5/10 mg IPI Q2w x12
8	Unresectable	Canceled	0	STx	iTum 5 mg IPI + 10 mg NIVO
9	Unresectable	Discontinued	3			IV 10 mg NIVO + iThe 10 mg NIVO + iThe 1/5/10 mg IPI Q2w x12

In the cohorts following cohort 1 and 2, an Ommaya reservoir was also implanted at the end of the surgery with the catheter hanging freely in the resection cavity, allowing to additionally perform intracavitary injections of nivolumab (cohorts 3 to 6) and the combination of nivolumab and ipilimumab (cohort 7). Cohorts 3, 6, and 8 allowed for the inclusion of patients with unresectable recurrent glioblastoma but with a preexisting resection cavity. Local injection in these patients was performed by stereotactic needle. In cohorts 5 and 6, BDCA1+ and BDCA3+ positive myeloid dendritic cells, obtained through leukapheresis, were injected intracerebrally at the end of the surgery, in addition to ipilimumab and nivolumab. From cohort 3 onwards, cerebrospinal fluid from the peritumoral area is obtained every two weeks, allowing cytological and also pharmacological analysis. MSR, Maximally Safe Resection; STx, stereotactic biopsy; iCer, intracerebral injection; iTum, intraTumoral injection; iCav, intracavitary injection; NIVO, Nivolumab; IPI, Ipilimumab.